Co-Inhibition of PARP and STAT3 as a Promising Approach for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triple-negative breast cancer (TNBC) is aggressive with limited treatment options.
• Olaparib (PARP inhibitor) treats germline BRCA-mutated TNBC, but resistance and limited use in non-BRCA TNBC are clinical challenges.
• Interleukin-6/STAT3 (IL-6/STAT3) signaling activation is linked to therapeutic resistance.

Purpose of the Study:

• To evaluate the combined effects of olaparib and the STAT3 inhibitor LLL12B in human TNBC cell lines.
• To investigate the efficacy of this combination therapy in TNBC with both BRCA mutations and wild-type BRCA status.

Main Methods:

• Utilized human TNBC cell lines with varying BRCA mutation statuses.
• Assessed the impact of olaparib and LLL12B, individually and in combination, on cell viability, migration, and invasion.
• Employed ELISA to measure IL-6 levels and MTT assays to evaluate cell viability.

Main Results:

• Olaparib treatment increased IL-6 levels in TNBC cells (2- to 39-fold).
• Inhibiting or knocking down STAT3 sensitized TNBC cells to olaparib.
• Combined olaparib and LLL12B administration significantly enhanced the inhibition of TNBC cell viability, migration, and invasion compared to single-agent treatments.
• This enhanced effect was observed irrespective of BRCA mutation status.

Conclusions:

• Dual inhibition of PARP and STAT3 presents a promising therapeutic strategy for TNBC.
• This combination approach shows potential for both BRCA-mutant and BRCA-proficient TNBC.
• Targeting the IL-6/STAT3 pathway can overcome resistance to PARP inhibitors in TNBC.